Changes in lymphocyte subsets following administration of interleukin 2 and cyclophosphamide in mice with transitional cell carcinoma

Oncol Res. 1997;9(2):71-5.

Abstract

We investigated the effects of combination therapy with interleukin 2(IL-2) and cyclophosphamide (CPM) in C3H/HeN mice implanted with mouse bladder tumor cells (MBT2). Tumor growth was suppressed in the mice treated with IL-2 alone and mice treated with CPM alone, although not completely. However, tumor growth was completely suppressed in the mice treated with both IL-2 and CPM. As for lymphocyte subset analysis of the spleen using flow cytometry, the frequency of Lyt2+ cells and asialo GM1+ cells was significantly higher in the mice treated with IL-2 and CPM compared to the other groups. In the lymphocyte subset analysis of the thymus, the frequency of L3T4-Lyt2+ cells was significantly lower in the mice treated with CPM alone and mice treated with IL-2 and CPM compared to the other groups.

MeSH terms

  • Animals
  • Carcinoma, Transitional Cell / immunology
  • Carcinoma, Transitional Cell / pathology
  • Carcinoma, Transitional Cell / therapy*
  • Cyclophosphamide / therapeutic use*
  • Flow Cytometry
  • Humans
  • Interleukin-2 / therapeutic use*
  • Lymphocyte Subsets / drug effects
  • Lymphocyte Subsets / immunology*
  • Male
  • Mice
  • Mice, Inbred C3H
  • Organ Size
  • Recombinant Proteins / therapeutic use
  • Spleen / drug effects
  • Spleen / immunology
  • Spleen / pathology
  • Thymus Gland / drug effects
  • Thymus Gland / immunology
  • Thymus Gland / pathology
  • Time Factors
  • Urinary Bladder Neoplasms / immunology
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / therapy*

Substances

  • Interleukin-2
  • Recombinant Proteins
  • Cyclophosphamide